News

SignalChem Lifesciences Corp. to Present Data on the Role of its AXL Inhibitor SLC-391 in Promoting Anti-Tumor Activity

April 9, 2018

•  AXL expression is up-regulated by transformed cells and the tumor microenvironment;
•  Up-regulation of AXL elicits an anti-inflammatory effect;
•  SLC-391 mediates a pro-inflammatory response by promoting a M2 to M1 transition; and
•  SLC-391 inhibits M2-induced epithelial mesenchymal transition (EMT).

Continue Reading

VANCOUVER, BRITISH COLUMBIA – April 9, 2018 – SignalChem Lifesciences Corporation (“SLC”) announced that it will present a poster detailing the preclinical data for its AXL inhibitor, SLC-391 at the AACR Annual Meeting, being held from April 14-18, 2018 in Chicago, IL.

Details of the poster to be presented are as follows:
Title: AXL inhibitor promotes anti-tumor immunity through modulation of macrophage polarization
Section: PO.ETO6.11 – Novel and Canonical Targets
Poster Session: Section 35
Date and Time: Tuesday, April 17; 8:00 AM – 12:00 PM
Presenter: Shenshen Lai, PhD. SignalChem Lifesciences Corporation

About SLC-391

SLC-391 is a selective small molecule inhibitor of AXL and other TAM family kinases (Tyro3 and Mer). Currently, IND-enabling GLP-toxicological studies are underway and are expected to be completed in Q3 2018. With favorable results, SignalChem plans to initiate Phase I clinical trials in Q4 2018.

About SLC

SLC is a privately held and clinical stage biotechnology company specializing in enabling personalized medicine strategies to improve human health. The company offers bio-reagents (tools and services used for research purposes) to organizations worldwide and leverages the internally developed enzyme technology platform to discover inhibitors of the untapped targets with a view of advancing these therapeutic programs into early clinical development stages. SLC’s current therapeutic development programs are related to hypoxia (cancer), specifically CAIX which is involved in mediating metastasis and AXL tyrosine kinase is involved in perpetuating resistance to standard chemo- and radiation therapy. SLC has established a strategic corporate alliance with Welichem Biotech Inc. to support the clinical development of its first program SLC-0111, a CAIX inhibitor for the treatment of metastatic cancer. A Phase 1B study evaluating SLC-0111 with gemcitabine in pancreatic cancer is expected to commence in Q2 2018. GLP toxicological studies for SLC’s second program, Axl inhibitor SLC-391, are currently underway with results to be expected in Q3 2018. SLC is actively seeking opportunities for a co-development partnership for the AXL program.

Forward-Looking Statements and Information

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.

The Terry Fox Laboratory and SignalChem Lifesciences to Present Data on the AXL Inhibitor SLC-0211 (SLC-391) at the 59th ASH Annual Meeting & Exposition

Dec. 8, 2017

•  Activation of the GAS6/AXL pathway plays a major role in the resistance to targeted therapies and conventional cytotoxic drugs;
•  Cells with high GAS6/AXL expression were more sensitive to SLC-0211 (SLC-391) than those with low GAS6 and/or AXL levels;
•  SLC-0211 (SLC-391) reduced colony forming cell (CFC) ability of CD34+ AML cells, but the inhibitory effect of SLC-0211 (SLC-391) was strikingly enhanced in re-plating assays, resulting in a significant reduction in re-plating efficiency of more primitive AML cells (75-97% inhibition) at doses that are not toxic to healthy cells;
•  Treatment with SLC-0211 (SLC-391) greatly reduced phosphorylation of AXLY779, AKTS473 and ERKT202/Y204 in AML cells in a dose-dependent manner as compared to control cells;
•  Targeting AXL is a promising strategy for AML cases characterized by populations of CD34+ cells that harbor specific mutations, coupled with elevated AXL/GAS6 activity.

Continue Reading

VANCOUVER, BRITISH COLUMBIA – Dec. 8, 2017 – SignalChem Lifesciences Corporation (“SLC”) announced that it will present a poster detailing the preclinical data for its AXL inhibitor, SLC-0211 (SLC-391) at the 59th ASH Annual Meeting & Exposition, being held from December 9 – 12, 2017 in Atlanta, Georgia.

Details of the poster to be presented are as follows:
Title: Targeting the GAS6/AXL Pathway with a Newly Developed, Selective AXL Inhibitor SLC-0211 in Acute Myeloid Leukemia Mutant Cells
Abstract Number: 616
Poster Session: Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II
Date and Time: Sunday, December 10; 6:00 PM - 8:00 PM
Presenter: Xiaojia Niu. Terry Fox Laboratory, British Columbia Cancer Agency; Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada; National Engineering Laboratory for AIDS Vaccine, Key Laboratory for Molecular Enzymology and Engineering, the Ministry of Education, School of Life Sciences, Jilin University, Changchun, P. R. China

About SLC-0211 (SLC-391)

SLC-0211 (SLC-391) is a selective small molecule inhibitor of AXL and other TAM family kinases (Tyro3 and Mer). Currently, IND-enabling GLP-toxicological studies are underway and are expected to be completed in Q4 2017. With favorable results, SignalChem plans to initiate Phase I clinical trials in Q3 2018.

About SLC

SLC is a privately held and clinical stage biotechnology company specializing in enabling personalized medicine strategies to improve human health. The company offers bio-reagents (tools and services used for research purposes) to organizations worldwide and leverages the internally developed enzyme technology platform to discover inhibitors of the untapped targets with a view of advancing these therapeutic programs into early clinical development stages. SLC’s current therapeutic development programs are related to hypoxia (cancer), specifically CAIX which is involved in mediating metastasis and AXL tyrosine kinase is involved in perpetuating resistance to standard chemo- and radiation therapy. SLC has established a strategic corporate alliance with Welichem Biotech Inc. to support the clinical development of its first program SLC-0111, a CAIX inhibitor for the treatment of metastatic cancer. A Phase 1B study evaluating SLC-0111 with gemcitabine in pancreatic cancer is expected to commence in Q1 2018. GLP toxicological studies for SLC’s second program, Axl inhibitor SLC-391, are currently underway with results to be expected in Q4, 2017. SLC is actively seeking opportunities for a co-development partnership for the AXL program.

Forward-Looking Statements and Information

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.

SignalChem Lifesciences to Present Data on the AXL Inhibitor SLC-391 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer

Oct. 25, 2017

•  SLC-391 inhibits CT-26 tumor growth by 37% in a 15-day efficacy study whereas PD-1 antibody delayed tumor growth by 27%;
•  Increases in the number of NK cells and the ratio of M1/M2-polarized macrophages were evident in the SLC-391 treatment group when compared to vehicle;
•  In combination with anti-PD1, SLC-391 significantly prolongs survival, reinforcing the implication of AXL inhibition in immuno-oncology.

Continue Reading

VANCOUVER, BRITISH COLUMBIA – Oct. 25, 2017 – SignalChem Lifesciences Corporation (“SLC”) announced that it will present a poster detailing the preclinical data for its AXL inhibitor, SLC-391 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held from October 26 – 30, 2017 in Philadelphia, Pennsylvania.

Details of the poster to be presented are as follows:
Title: Activity of the TAM kinase-targeting compound, SLC-391, is mediated by the engagement of the immune system in CT-26 syngeneic mouse model
Abstract Number: 522
Poster Session: PO.B10 – New Molecular Targets
Date and Time: Sunday, October 29; 12:30 – 4:00 PM
Presenter: Anthony Marotta, PhD. SignalChem Lifesciences Corporation

About SLC-391

SLC-391 is a selective small molecule inhibitor of AXL and other TAM family kinases (Tyro3 and Mer). Currently, IND-enabling GLP-toxicological studies are underway and are expected to be completed in Q4 2017. With favorable results, SignalChem plans to initiate Phase I clinical trials in Q3 2018.

About SLC

SLC is a privately held and clinical stage biotechnology company specializing in enabling personalized medicine strategies to improve human health. The company offers bio-reagents (tools and services used for research purposes) to organizations worldwide and leverages the internally developed enzyme technology platform to discover inhibitors of the untapped targets with a view of advancing these therapeutic programs into early clinical development stages. SLC’s current therapeutic development programs are related to hypoxia (cancer), specifically CAIX which is involved in mediating metastasis and AXL tyrosine kinase is involved in perpetuating resistance to standard chemo- and radiation therapy. SLC has established a strategic corporate alliance with Welichem Biotech Inc. to support the clinical development of its first program SLC-0111, a CAIX inhibitor for the treatment of metastatic cancer. A Phase 1B study evaluating SLC-0111 with gemcitabine in pancreatic cancer is expected to commence in Q1 2018. GLP toxicological studies for SLC’s second program, Axl inhibitor SLC-391, are currently underway with results to be expected in Q4, 2017. SLC is actively seeking opportunities for a co-development partnership for the AXL program.

Forward-Looking Statements and Information

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.

SignalChem Initiates Phase 1 Clinical Trial for SLC-0111 in Solid Tumours

Dec 4, 2014

SignalChem Lifesciences Corp. ("SLC"), has dosed its first patient in a Phase 1a clinical trial studying the safety and tolerability of SLC-0111. The study marks a significant clinical milestone for SLC. Taking a personalized medicine approach, the Company is developing SLC-0111 for the targeted treatment of various forms of cancer.

Continue Reading

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Dec 4, 2014) - SignalChem Lifesciences Corp. ("SLC"), has dosed its first patient in a Phase 1a clinical trial studying the safety and tolerability of SLC-0111. The study marks a significant clinical milestone for SLC. Taking a personalized medicine approach, the Company is developing SLC-0111 for the targeted treatment of various forms of cancer. SLC-0111 is a proprietary small molecule that selectively targets CAIX enzyme within the hypoxic regions of the tumour. Hypoxic areas of tumours host aggressive cancer cells that are resistant to conventional therapies and CAIX plays a critical role in their survival. No drug therapies currently exist for blocking CAIX enzyme activity in hypoxic areas of solid tumours. "There is currently a significant unmet need for a treatment that could decrease the survival of cancer cells in the hypoxic regions of a tumour, said Jasbinder Sanghera, PhD., CEO of SLC. "Targeting the CAIX enzyme represents a promising new approach for treating and preventing tumour growth, especially recurrence, and SLC is the first company that has demonstrated success in reaching these difficult areas of the tumour. This therapy could provide a meaningful benefit to cancer patients." The initiation of clinical development for SLC-0111 follows extensive research and preclinical studies where the compound demonstrated consistently positive effects for the treatment of various tumours. "Our studies have demonstrated that SLC-0111 may work well in effectively stopping and shrinking various tumours, prevent recurrence, metastases, and cancer stem cell survival, commented Dr. Shoukat Dedhar, one of the original developers of the program, distinguished scientist and the Professor of the Department of Integrative Oncology, BC Cancer Research Centre and University of British Columbia. "This program may prove to be a major step forward in treating both tumour growth and spread in a segment of the tumour, which if left untreated, has a devastating impact on patients." SLC is also developing a backup small molecule inhibitor of CAIX (SLC-021) and in collaboration with the National Research Council of Canada, a monoclonal antibody (SLC-0131) targeting CAIX. Both programs are in the preclinical development stage.

About the Phase 1 Trial

The Phase 1a trial is a dose escalation study and the Company will enroll up to 30 cancer patients with refractory solid tumours. The study is being conducted by Ozmosis Research Inc., Toronto, ON with sites located at The Princess Margaret in Toronto, Ontario, the Cross Cancer Institute in Edmonton, Alberta and the BC Cancer Agency in Vancouver, BC. The primary objective is to investigate the safety and tolerability of SLC-0111. The company plans to start Phase 1b studies later in 2015. These trials will involve selecting patients whose tumours express CAIX and treating only these patients with SLC-0111.

About CAIX

SLC has identified and validated the metalloenzyme Carbonic Anhydrase IX (CAIX), which is expressed selectively on the cell surface of hypoxic (oxygen depleted) tumour cells particularly cancer stem cells, and is one of the major factors contributing to cancer cell survival and metastasis. The role of CAIX is to catalyse the reversible hydration of carbon dioxide to bicarbonate and protons: H2O + CO2 to HCO3- + H+.

About SLC

SignalChem Lifesciences ("SLC") discovers and develops drug candidates using a personalized medicine approach. We identify patients with a specific kinase defect and then select a relevant targeted therapy against the defective kinase. SLC's development process selects the most relevant kinase targets for drug development and identifies the best compound from our kinase specific chemical library. This ensures best-in-class potency and superior selectivity; yielding highly effective drug candidates with greatly reduced side effects. Our approach has the potential to provide a much more effective therapy and allows SLC to apply the therapy to only those patients who are most likely to receive a meaningful clinical benefit. For more information please visit www.signalchemcorp.com.

Forward-Looking Statements and Information

This release contains forward-looking statements that are not based on historical facts. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied. Readers are cautioned not to place undue reliance on such forward-looking statements.